Sign in

You're signed outSign in or to get full access.

Jill Taymans

Chief Financial Officer at CRYO CELL INTERNATIONAL
Executive

About Jill Taymans

Jill M. Taymans is Vice President, Finance and Chief Financial Officer of Cryo-Cell International, Inc. (CCEL). She joined the company in April 1997 as Controller and was appointed CFO in May 1998; she is 55 years old and holds a BS in Accounting from the University of Maryland (1991), with over 30 years of accounting experience across public and private sectors, including three years as Controller for a telecommunications company prior to CCEL . She provides Sarbanes-Oxley certifications on CCEL’s quarterly and annual filings, underscoring accountability for financial reporting and controls .

Past Roles

OrganizationRoleYearsStrategic Impact
Cryo-Cell International, Inc.ControllerApr 1997–May 1998 Built accounting foundation ahead of CFO promotion
Cryo-Cell International, Inc.Chief Financial OfficerMay 1998–Present Oversees financial reporting, controls, and capital allocation; SOX certifications

External Roles

No external public company directorships or committee roles are disclosed in the proxy biography for Ms. Taymans .

Fixed Compensation

Multi-year summary (fiscal years ended November 30):

MetricFY 2022FY 2023FY 2024
Salary ($)$215,000 $234,769 $280,000
Bonus ($)$12,985 $20,000 $20,000
Stock Awards ($)$0 $0 $0
Option Awards ($)$5,383 $52,535 $22,931
Total ($)$233,368 $307,304 $322,931

Notes:

  • Compensation philosophy relies on competitive base pay plus discretionary cash bonuses and stock options, reviewed by the Compensation Committee against company and individual performance .

Performance Compensation

Subjective annual bonus rubric and payouts:

YearMetricWeightingTargetActual (Company/Exec)Payout ($)Vesting
FY 2023Discretionary performance review across competencies (leadership, team-building, accountability, analytics, communication, creativity/problem-solving, integrity) Discretionary Not specified Committee-evaluated $20,000 Cash
FY 2024Discretionary performance review across competencies (as above) Discretionary Not specified Committee-evaluated $20,000 Cash

Option awards and vesting conditions (Outstanding at Nov 30, 2024):

Grant DateOptions (#)Exercise Price ($)ExpirationVesting Schedule
Jun 2, 20167,500 3.10 Jun 3, 2026 1/3 immediate, 1/3 at 1 year, 1/3 at 2 years
Sep 23, 20207,000 8.00 Sep 23, 2027 1/3 at 1 year, 1/3 at 2 years, 1/3 at 3 years
Jan 13, 202320,000 4.62 Jan 13, 2028 Vest immediately upon issuance
Dec 22, 202310,000 5.88 Dec 22, 2028 1/3 immediate, 1/3 at 1 year, 1/3 at 2 years

Equity Ownership & Alignment

Beneficial ownership and alignment indicators:

As-of DateShares Beneficially OwnedPercent of ClassOptions Exercisable Within 60 Days
Sep 20, 202483,229 1.03% 37,833
Sep 15, 202589,896 1.11% Not disclosed

Additional context:

  • Ownership percentages computed per SEC Rule 13d‑3 using shares outstanding and options exercisable within 60 days .

Employment Terms

Key terms of the Taymans Employment Agreement:

TermDetail
Agreement StartOriginal agreement Nov 1, 2005; amended July 2008 to expire Nov 30, 2008; current term ends Nov 30, 2026; one-year auto-renew unless non-renewal notice ≥60 days before term end
Base Salary$280,000 (current)
Bonus EligibilityDiscretionary annual bonuses at Compensation Committee’s discretion
Long-Term IncentivesEligible for long-term incentive awards provided to senior executives, terms set by Compensation Committee
Change-in-Control SeveranceIf terminated without cause or due to demotion/relocation upon or within 1 year of a Change in Control (or prior if related), entitled to all earned compensation through termination date and 12 months of base salary; continued participation in benefit plans; reasonable business expenses
Restrictive CovenantsNon-compete and non-solicitation for 12 months post-termination

Investment Implications

  • Pay-for-performance alignment is modest but present: the CFO’s cash bonuses are discretionary and relatively small versus base, while equity incentives are primarily time-based stock options with clear vesting ladders; at least one grant vested immediately, creating potential for near-term liquidity decisions once options are in-the-money .
  • Ownership alignment: Ms. Taymans beneficially owns ~1.11% of CCEL, up from ~1.03% in the prior year, indicating increasing skin-in-the-game; options exercisable within 60 days were disclosed in 2024 and included in ownership calculations, reinforcing alignment via option exposure .
  • Retention and change-of-control economics: Her CoC protection is limited to 12 months of base salary plus continuation of benefits, materially lower than the Co-CEOs’ 2x salary plus bonus constructs; this suggests lower payout risk and manageable retention cost, with standard 12-month non-compete/non-solicit provisions .
  • Monitoring catalysts: Option expirations in 2026 and 2027 (and 2028) create focal points to track potential exercises and subsequent Form 4 activity; investors should monitor insider trading filings around vesting anniversaries and expirations for selling pressure signals .